Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting
Stock Information for Akari Therapeutics Plc
Loading
Please wait while we load your information from QuoteMedia.